Purdue's ‘Duplicative’ Suit Over OxyContin Generic Gets Ax
Law360, Boston (January 16, 2018, 6:29 PM EST) -- Tweaks to a generic opioid’s labeling did not warrant OxyContin maker Purdue Pharma LP to file a separate lawsuit repeating extant patent infringement claims, a federal judge decided in a Boston court hearing Tuesday.
U.S. District Judge F. Dennis Saylor IV said that one of three lawsuits from opioid giant Purdue defending OxyContin’s intellectual territory used a generic competitor’s supplemental New Drug Application to rehash old claims. He dismissed the suit.
With the decision, Collegium Pharmaceutical Inc. avoided stalling a label change indicating that its generic painkiller, Xtampza ER, was more difficult to abuse than OxyContin.
“If the supplemental NDA is...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!